Aggression
Conditions
Brief summary
Aggressive behaviours are highly prevalent among people with developmental disabilities, both in community and inpatient or residential settings, with adverse consequences for the individuals involved and others. Some predictive factors, particularly impulsivity, are dynamic with neurobiological underpinnings, and as such amenable to change or neuromodulation using non-invasive brain stimulation techniques. With this in mind, we designed an experimental protocol to determine the efficacy of transcranial Direct Current Stimulation (tDCS) as a non-invasive brain stimulation technique to reduce impulsivity and aggression associated with developmental disability.
Detailed description
This study aims to assess the efficacy of anodal tDCS in modulating Rapid Response Impulsivity (RRI) and reducing incidents of aggression in people with developmental disabilities is residential or hospital settings. Using a single blind, parallel arms, randomized controlled trial design, adults (n=60) aged 18 to 65 with developmental disabilities, who have a history of impulsivity leading to aggression, will be randomised to receive either repetitive anodal or sham tDCS. Enrolled participants will receive either three treatment sessions of tDCS or sham tDCS. Behavioural and impulsivity will be measured before and immediately after treatment, one week, and one month after treatment end. Data will be analysed in SPSS using repeated measures ANOVA.
Interventions
DEVICETranscranial Direct Current Stimulation
non-invasive brain stimulator
Sponsors
Dr. Najat Khalifa
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Adults aged 18-64 years * Diagnosis of a developmental disability * History of one or more incidents of aggression in the last month * Consent to participate in the trial by the individual or their Substitute Decision Maker
Exclusion criteria
* History of epilepsy or seizures * History of acquired brain injury * Having metal in the brain/skull, e.g. splinters, fragments or clips * Having a cochlear implant * Having an implanted neuro-stimulator (e.g. direct brain stimulation, epidural/subdural stimulation, vagal nerve stimulation) * History of brain surgery of procedure * History of severe adverse reaction to tDCS * Having a cardiac pacemaker or intracardiac lines * Current alcohol or drug misuse * Having a sensitive scalp
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Aggression | change from baseline one week and one month after the third tDCS session | To determine the effect of tDCS treatment on aggressive symptoms measured by The Modified Overt Aggression Scale (MOAS); Total weighted scores range from 0-40, with a higher score indicating more aggressive behavior. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maladaptive behaviors | change from baseline one week and one month after the third tDCS session | Behavior Problems Inventory (BPI); The total frequency scores range from 0-120 and severity of self-injurious behaviour and aggression subscales from 18-54, with higher scores indicating higher frequency and severity |
| Intervention side effects | Up to 72hrs after the first, second, and third active or sham tDCS treatments. | Tracking potential side effects of tDCS/sham treatments using tDCS adverse effects questionnaire. |
| Trait Impulsivity | Baseline | Barratt Impulsiveness Scale-11 (BIS-11); The total scores range from 30 - 120, with higher scores indicating higher impulsivity. |
| Impulsivity | change from baseline and the same day after the third tDCS sessions | To determine the effects of tDCS treatment on symptoms of impulsivity measured by the Stop Signals Task (SST) |
| Treatment Acceptability | Up to 72hrs after the third active or sham tDCS treatments. | Total scores on the tDCS Treatment Acceptability Questionnaire |
Countries
Canada
Contacts
CONTACTNajat Khalifa, MD
CONTACTAndrew Bickle, MD
STUDY_CHAIRMuhammad Ayub, MD
Queen's University
Outcome results
None listed